Take a look through some of the notable data presentations at this year's ESMO Congress.
|Articles|September 1, 2002
Up to 40% of cancers may not present clinically
Author(s)Scott Tennant
Seattle-Despite the way it was portrayed in some of the lay media, the authors of a recent study on the "overdiagnosis" of prostate cancer insist their work should not be construed as hostile to the practice of PSA screening. In fact, says one investigator, results of the study paint an overall favorable picture of screening.
Advertisement
Advertisement
Related to this article
The investigational HIF-2α inhibitor casdatifan demonstrated antitumor activity as monotherapy and in combination regimens across the ARC-20 platform study.
The agency issued a PDUFA target action date of June 14, 2027.
Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.
Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adherence.
Long-term QUILT-3.032 findings show durable responses with Anktiva plus BCG in BCG-unresponsive NMIBC, with an estimated 84.2% cystectomy-free survival at 3 years.
Vignesh Packiam, MD, discusses strategies to manage intravesical therapy toxicity in NMIBC, improve treatment tolerability, and preserve bladder function.
Sandip M. Prasad, MD, MPhil, discusses the safety profile of mitomycin intravesical solution, including common adverse events and patient counseling during chemoablation for NMIBC.
Advertisement
Advertisement
Trending on Urology Times
1
ESMO 2026: Key presentations across genitourinary oncology
2
Casdatifan shows activity across treatment settings in advanced ccRCC
3
Jeffrey M. Spier, MD, on the evidence for reduced-dose enzalutamide
4
FDA accepts new drug application for UGN-103 in recurrent LG-IR-NMIBC
5